- Report
- July 2024
- 135 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2021
- 117 Pages
United States
From €4505EUR$4,950USD£3,827GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
- Report
- May 2022
- 284 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
Methohexital is a barbiturate anesthetic drug used to induce general anesthesia. It is a short-acting drug, meaning it has a rapid onset and short duration of action. It is commonly used in combination with other anesthetic drugs to provide a balanced anesthetic effect. It is also used to treat seizures and to induce unconsciousness prior to surgery. Methohexital is available in both intravenous and intramuscular forms.
Methohexital is a commonly used anesthetic drug in the operating room. It is used to provide a balanced anesthetic effect and to induce unconsciousness prior to surgery. It is also used to treat seizures and to provide sedation for certain medical procedures.
The Methohexital market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Hospira, Mylan, Teva Pharmaceuticals, Fresenius Kabi, and Baxter International. Show Less Read more